NRD
CORT icon

Nebula Research & Development’s Corcept Therapeutics CORT Stock Holding History

Nebula Research & Development’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,791
Closed -$433K – 984
2025
Q1 		$433K Sell
3,791
-7,787
-67% -$474K 0.04% 650
2024
Q4 		$583K Buy
+11,578
New +$607K 0.07% 495

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nebula Research & Development's CORT Position: Q2 2025 in Review

Nebula Research & Development sold out of Corcept Therapeutics (CORT) in Q2 2025, closing a stake of 3,791 shares — an estimated $433K sold.

Nebula Research & Development first reported a position in CORT in Q4 2024 and held it in 2 quarters. The position peaked at $583K in Q4 2024. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.

  • Nebula Research & Development reported no remaining Corcept Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nebula Research & Development sold 3,791 Corcept Therapeutics shares in Q2 2025, an estimated $433K.
  • Nebula Research & Development first reported a position in Corcept Therapeutics in Q4 2024 and held it in 2 quarters.
  • Nebula Research & Development's Corcept Therapeutics position peaked at $583K in Q4 2024.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.

Based on Nebula Research & Development's 13F filing for Q2 2025, filed 14 Aug 2025.